<DOC>
	<DOCNO>NCT01371617</DOCNO>
	<brief_summary>The purpose study determine safety efficacy IPI-926 patient myelofibrosis ( MF ) ( primary myelofibrosis [ PMF ] , post-polycythemia vera myelofibrosis [ post-PV MF ] , post-essential thrombocythemia myelofibrosis [ post-ET MF ] ) .</brief_summary>
	<brief_title>A Phase 2 Study With IPI-926 Patients With Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Veratrum Alkaloids</mesh_term>
	<criteria>≥18 year age time sign ICF . Voluntarily sign ICF . Pathologically confirm PMF post ET/PV MF per WHO diagnostic criterion ( note must include least Grade 1 marrow fibrosis , see Appendix 3 ) intermediate1 , intermediate 2 , high risk disease accord IWG prognostic scoring system ( see Appendix 4 ) . If patient low risk disease , must symptomatic splenomegaly ≥ 10 cm leave costal margin physical exam . ECOG performance 02 . Life expectancy least 3 month . Recovery Grade 1 baseline toxicity due prior systemic treatment , exclude alopecia . If woman , nonchild bear potential , woman childbearing potential ( WCBP ) ( define sexually mature woman undergone surgical sterilization naturally postmenopausal least 24 consecutive month woman ≤55 year ; woman &gt; 55 year 12 consecutive month ) , must negative serum urine pregnancy test result within 2 week first dose study drug . All WCBP sexually active male patient must agree use adequate method birth control throughout study . Adequate method contraception include use oral contraceptive additional barrier method , double barrier method ( diaphragm spermicidal gel condom contraceptive foam ) , DepoProvera , partner vasectomy , total abstinence . Ability adhere study visit schedule protocol requirement . Prior treatment inhibitor hedgehog pathway ( e.g . GDC0449 ) . Received treatment myelofibrosis within 2 week study entry . Other invasive malignancy diagnose within last 3 year , except nonmelanoma skin cancer localize cured prostate cervical cancer . Inadequate hepatic function define : Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) . Direct bilirubin &gt; 1.5 x ULN . Cirrhotic liver disease , ongoing alcohol abuse , know chronic active acute hepatitis . Inadequate renal function define serum creatinine &gt; 2 x ULN . History stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication mechanical control within last 6 month . Presence active infection systemic use antibiotic within 72 hour treatment . Significant comorbid condition disease , judgment Investigator , would place patient undue risk interfere study . Known human immunodeficiency virus ( HIV ) positivity . Known hypersensitivity IPI926 , excipients IPI926 capsule . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>IPI-926</keyword>
	<keyword>926</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Hedgehog</keyword>
	<keyword>Infinity Pharmaceuticals</keyword>
	<keyword>Post Essential thrombocythemia</keyword>
	<keyword>Post Polycythemia vera</keyword>
</DOC>